These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 23028850)

  • 21. Dendritic cells preferentially transfer CXCR4-using human immunodeficiency virus type 1 variants to CD4+ T lymphocytes in trans.
    van Montfort T; Thomas AA; Pollakis G; Paxton WA
    J Virol; 2008 Aug; 82(16):7886-96. PubMed ID: 18524826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. V3 loop-determined coreceptor preference dictates the dynamics of CD4+-T-cell loss in simian-human immunodeficiency virus-infected macaques.
    Ho SH; Shek L; Gettie A; Blanchard J; Cheng-Mayer C
    J Virol; 2005 Oct; 79(19):12296-303. PubMed ID: 16160156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor.
    Derdeyn CA; Decker JM; Sfakianos JN; Zhang Z; O'Brien WA; Ratner L; Shaw GM; Hunter E
    J Virol; 2001 Sep; 75(18):8605-14. PubMed ID: 11507206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Affinofile profiling: how efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV.
    Chikere K; Chou T; Gorry PR; Lee B
    Virology; 2013 Jan; 435(1):81-91. PubMed ID: 23217618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4.
    Cho MW; Lee MK; Carney MC; Berson JF; Doms RW; Martin MA
    J Virol; 1998 Mar; 72(3):2509-15. PubMed ID: 9499115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
    Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
    J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.
    Borm K; Jakobsen MR; Cashin K; Flynn JK; Ellenberg P; Ostergaard L; Lee B; Churchill MJ; Roche M; Gorry PR
    Retrovirology; 2016 Nov; 13(1):74. PubMed ID: 27809912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
    Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. gp120 induces cell death in human neuroblastoma cells through the CXCR4 and CCR5 chemokine receptors.
    Catani MV; Corasaniti MT; Navarra M; Nisticò G; Finazzi-Agrò A; Melino G
    J Neurochem; 2000 Jun; 74(6):2373-9. PubMed ID: 10820198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Palmitic Acid Is a Novel CD4 Fusion Inhibitor That Blocks HIV Entry and Infection.
    Lee DY; Lin X; Paskaleva EE; Liu Y; Puttamadappa SS; Thornber C; Drake JR; Habulin M; Shekhtman A; Canki M
    AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1231-41. PubMed ID: 20001317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro.
    Moncunill G; Armand-Ugón M; Pauls E; Clotet B; Esté JA
    AIDS; 2008 Jan; 22(1):23-31. PubMed ID: 18090388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lignosulfonic acid exhibits broadly anti-HIV-1 activity--potential as a microbicide candidate for the prevention of HIV-1 sexual transmission.
    Qiu M; Wang Q; Chu Y; Yuan Z; Song H; Chen Z; Wu Z
    PLoS One; 2012; 7(4):e35906. PubMed ID: 22558266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Biological characteristics of HIV-1 isolates circulating in China are linked to its env V3 loop sequence variability].
    Hei FX; Hong KX; Song YH; Tang HL; Peng H; Xu JQ; Xing H; Shao YM
    Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(23):1968-72. PubMed ID: 15730807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
    Murray EJ; Leaman DP; Pawa N; Perkins H; Pickford C; Perros M; Zwick MB; Butler SL
    J Virol; 2010 Jul; 84(14):7288-99. PubMed ID: 20427524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineered CD4- and CXCR4-using simian immunodeficiency virus from African green monkeys is neutralization sensitive and replicates in nonstimulated lymphocytes.
    König RR; Flory E; Steidl S; Neumann J; Coulibaly C; Holznagel E; Holzammer S; Norley S; Cichutek K
    J Virol; 2002 Nov; 76(21):10627-36. PubMed ID: 12368305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genotypic coreceptor analysis.
    Sierra S; Kaiser R; Thielen A; Lengauer T
    Eur J Med Res; 2007 Oct; 12(9):453-62. PubMed ID: 17933727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design of HIV Coreceptor Derived Peptides That Inhibit Viral Entry at Submicromolar Concentrations.
    Bobyk KD; Mandadapu SR; Lohith K; Guzzo C; Bhargava A; Lusso P; Bewley CA
    Mol Pharm; 2017 Aug; 14(8):2681-2689. PubMed ID: 28494151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.
    Dogo-Isonagie C; Lam S; Gustchina E; Acharya P; Yang Y; Shahzad-ul-Hussan S; Clore GM; Kwong PD; Bewley CA
    J Biol Chem; 2012 Apr; 287(18):15076-86. PubMed ID: 22403408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolution of coreceptor utilization to escape CCR5 antagonist therapy.
    Zhang J; Gao X; Martin J; Rosa B; Chen Z; Mitreva M; Henrich T; Kuritzkes D; Ratner L
    Virology; 2016 Jul; 494():198-214. PubMed ID: 27128349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity.
    LaBranche CC; Hoffman TL; Romano J; Haggarty BS; Edwards TG; Matthews TJ; Doms RW; Hoxie JA
    J Virol; 1999 Dec; 73(12):10310-9. PubMed ID: 10559349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.